Sign In
Buy XOMA
$41.70
+0.0100 (+0.0240%)
At Close: Jun 03, 2026
XOMA Royalty Declares Quarterly Preferred Stock Dividends
07:30am, Monday, 22'nd Dec 2025
EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash
XOMA Royalty Enters into Agreement to Acquire Generation Bio
05:00pm, Monday, 15'th Dec 2025
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna -
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
09:00am, Friday, 05'th Dec 2025
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its pr
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
07:45am, Friday, 05'th Dec 2025
WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter
Mural Oncology Announces Sanction of the Scheme by the High Court
04:30pm, Wednesday, 03'rd Dec 2025
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement b
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
09:00am, Wednesday, 26'th Nov 2025
WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
07:45am, Friday, 21'st Nov 2025
EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Wednesday, 12'th Nov 2025
XOMA Royalty (XOMA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.39 per share a year ago.
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
07:30am, Wednesday, 12'th Nov 2025
Business development : Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics.
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
04:09pm, Monday, 10'th Nov 2025
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed
Financial Survey: Cognition Therapeutics (NASDAQ:CGTX) versus XOMA Royalty (NASDAQ:XOMA)
02:49am, Sunday, 26'th Oct 2025
Cognition Therapeutics (NASDAQ: CGTX - Get Free Report) and XOMA Royalty (NASDAQ: XOMA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO
Compass Therapeutics (NASDAQ:CMPX) & XOMA Royalty (NASDAQ:XOMA) Head-To-Head Survey
01:48am, Wednesday, 22'nd Oct 2025
Compass Therapeutics (NASDAQ: CMPX - Get Free Report) and XOMA Royalty (NASDAQ: XOMA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
11:45am, Friday, 17'th Oct 2025
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Nether
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
08:00am, Friday, 03'rd Oct 2025
XOMA Royalty Corporation preferred stocks offer diversification beyond mREITs and banks, but both XOMAO and XOMAP are now rated Sell. Recent high-cost financing and low tangible common equity raise ri
